丙戊酸镁联合帕利哌酮治疗精神分裂症的临床效果

摘要
图/表
参考文献(18)
相关文章 (15)

全文: PDF (586 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的评价丙戊酸镁联合帕利哌酮治疗精神分裂症的临床效果。方法选取2020年10月至2021年8月江西省精神病院收治的86例精神分裂症患者作为研究对象，按照随机数字表法将其分为对照组（43例）与观察组（43例），对照组采用帕利哌酮治疗，观察组采用丙戊酸镁联合帕利哌酮治疗，疗程3个月。比较两组患者的临床疗效、阳性和阴性症状（PANSS）评分、功能大体评价量表（GAF）评分、社会功能缺陷筛选量表（SDSS）评分、硫代巴比妥酸反应物（TBARS）、脑源性神经营养因子（BDNF）、肿瘤坏死因子-α（TNF-α）、白介素-1β（IL-1β）和不良反应。结果观察组患者的治疗总有效率高于对照组，差异有统计学意义（P＜0.05）。治疗后，两组患者的GAF评分高于治疗前，PANSS评分、SDSS评分低于治疗前，且观察组患者的GAF评分高于对照组，PANSS评分、SDSS评分低于对照组，差异有统计学意义（P＜0.05）。治疗后，两组患者的TBARS、TNF-α和IL-1β水平均低于治疗前，BDNF水平高于治疗前，且观察组患者的TBARS、TNF-α和IL-1β水平均低于对照组，BDNF水平高于对照组，差异有统计学意义（P＜0.05）。两组患者的不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论丙戊酸镁联合帕利哌酮治疗精神分裂症的效果确切。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李淑娟
	胡静
	涂刚英
	李俊毅

关键词 ：丙戊酸镁, 帕利哌酮, 精神分裂症, 硫代巴比妥酸反应物, 脑源性神经营养因子

Abstract： Objective To evaluate the clinical effects of Magnesium Valproate combined with Paliperidone in the treatment of schizophrenia. Methods A total of 86 patients with schizophrenia treated in Jiangxi Psychiatric Hospital from October 2020 to August 2021 were selected as research objects, and they were divided into control group (43 cases) and observation group (43 cases) according to random number table method. The control group was treated with Paliperidone, and the observation group was treated with Magnesium Valproate combined with Paliperidone. The course of treatment was three months. The clinical efficacy, positive and negative symptom score (PANSS), global assessment function (GAF) score, social disability screening schedule (SDSS) score, thiobarbituric acid reactive substances (TBARS), brain-derived neurotrophic factor (BDNF), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P<0.05). After treatment, GAF score of the two groups was higher than that before treatment, PANSS score and SDSS score of the two groups were lower than those before treatment, and GAF score of the observation group was higher than that of the control group, PANSS score and SDSS score of the observation group were lower than those of the control group, the difference was statistically significant (P<0.05). After treatment, the levels of TBARS, TNF-α and IL-1β in two groups were lower than those before treatment, the level of BDNF in two groups was higher than that before treatment, and the levels of TBARS, TNF-α and IL-1β in the observation group were lower than those in the control group, the level of BDNF in the observation group was higher than that in the control group, the difference was statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Magnesium Valproate combined with Paliperidone is effective in the treatment of schizophrenia.

Key words： Magnesium Valproate Paliperidone Schizophrenia Thiobarbituric acid reactive substances Brain-derived neurotrophic factor

基金资助:江西省卫生健康委科技计划项目（SKJP2202112 29）。

通讯作者: ▲通讯作者

引用本文:

李淑娟；胡静；涂刚英；李俊毅. 丙戊酸镁联合帕利哌酮治疗精神分裂症的临床效果[J]. 中国当代医药, 2022, 29(19): 81-84.
LI Shujuan； HU Jing； TU Gangying； LI Junyi. Clinical effects of Magnesium Valproate combined with Paliperidone in the treatment of schizophrenia. 中国当代医药, 2022, 29(19): 81-84.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I19/81

[1]	屈金梅.阿立哌唑与利培酮治疗精神分裂症的临床效果及对糖脂代谢的影响比较[J].中国当代医药，2021，28（34）：173-176.
[2]	李凤珍，郑素芬，梁梅菊.个案管理模式对慢性住院精神分裂症患者康复的影响[J].中国当代医药，2021，28（6）：180-182.
[3]	张驰，兰智勇，兰吴沅，等.帕利哌酮联合丙戊酸钠对神经认知障碍患者精神症状的疗效观察[J].浙江医学，2020， 42（10）：1061-1063.
[4]	李和军.乌灵胶囊联合帕利哌酮对精神分裂症患者血清炎症因子和神经功能的影响[J].药物评价研究，2020，43（6）：1086-1090.
[5]	善耀萩.小剂量丙戊酸镁联合抗精神病药物治疗精神分裂症患者攻击行为的临床效果分析[J].系统医学，2021，6（5）：39-42.
[6]	李功迎，宋思佳，曹龙飞.精神障碍诊断与统计手册第5版解读[J].中华诊断学电子杂志，2014，2（4）：310-312.
[7]	朱明，宋传福.慢性精神分裂症患者血清SOD，BDNF，PANSS量表评分及临床意义[J].中国医药导报，2020，17（23）：118-121.
[8]	赵丽琼，张跃坤，黄芹，等.社区严重精神障碍患者死亡状况与社会功能水平相关性分析[J].中国社区医师，2017， 33（13）：37-38.
[9]	郭馨心.精神分裂症社会认知及社会功能研究[D].济宁：济宁医学院，2019.
[10]	吕爽，张献强，刘佳，等.低频经颅磁刺激联合利培酮对精神分裂症患者的妄想症状疗效及不良反应研究[J].中国医学创新，2020，17（2）：109-112.
[11]	梁云飞，郭雪琴，陈健，等.早期干预对首发精神分裂症疗效及持续用药时间研究[J].中国医学创新，2020，17（13）：131-134.
[12]	甘记兴，李永瑾，庞德兵.小剂量丙戊酸镁联合帕利哌酮缓释片对精神分裂症患者神经营养因子水平的影响[J].中华保健医学杂志，2021，23（4）：366-369.
[13]	Sigitova E，Fisar Z，Hroudová J，et al.Biological hypotheses and biomarkers of bipolar disorder[J].Psychiatry Clin Neu-rosci，2017，71（2）：77-103.
[14]	Scaini G，Rezin GT，Carvalho AF，et al.Mitochondrial dysfunction in bipolar disorder：evidence，pathophysiology and translational implications[J].Neuroscie Biobehav Rev，2016，68：694-713.
[15]	温亚平，刘小彩，郑克，等.首发精神分裂症外周血BDNF与认知功能的相关研究[J].中国现代医生，2016，54（7）：8-11.
[16]	Baganz NL，Blakely RD.A dialogue between the immune system and brain，spoken in the language of serotonin[J].ACS Chem Neurosci，2013，4（1）：48-63.
[17]	González-Blanco L，García-Portilla MP，García-álvarez L，et al. Can interleukin-2 and interleukin-1β be specific biomarkers of negative symptoms in schizophrenia[J].Rev Psiquiatr Salud Ment，2019，12（1）：9-16.
[18]	Goldsmith DR，Rapaport MH，Miller BJ.A meta-analysis of blood cytokine network alterations in psychiatric patients：comparisons between schizophrenia，bipolar disorder and depression[J].Mol Psychiatry，2016，21（12）：1696-1709.